BACKGROUND: Pazopanib, an anti-angiogenic multitarget tyrosine kinase inhibitor, has been approved for the treatment of metastatic renal cell carcinoma and soft tissue sarcoma. However, its recommended dose does not always produce consistent outcomes, with some patients experiencing adverse effects or toxicity. This variability is due to differences in the systemic exposure to pazopanib. This review aimed to establish whether sufficient evidence exists for the routine or selective therapeutic drug monitoring of pazopanib in adult patients with approved indications. METHODS: A systematic search of the PubMed and Web of Science databases using search terms related to pazopanib and therapeutic drug monitoring yielded 186 and 275 articles, respectively. Ten articles associated with treatment outcomes or toxicity due to drug exposure were selected for review. RESULTS: The included studies were evaluated to determine the significance of the relationship between drug exposure/Ctrough and treatment outcomes and between drug exposure and toxicity. A relationship between exposure and treatment outcomes was observed in 5 studies, whereas the trend was nonsignificant in 4 studies. A relationship between exposure and toxicity was observed in 6 studies, whereas 2 studies did not find a significant relationship; significance was not reported in 3 studies. CONCLUSIONS: Sufficient evidence supports the therapeutic drug monitoring of pazopanib in adult patients to improve its efficacy and/or safety in the approved indications.

Department of Biochemistry Faculty of Medicine Masaryk University Brno Czech Republic

Department of Biochemistry Faculty of Science Masaryk University Brno Czech Republic

Department of Clinical Pharmacy University Hospital Ostrava Ostrava Czech Republic

Department of Pharmacology and Toxicology Faculty of Pharmacy Masaryk University Brno Czech Republic

Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic

Masaryk Memorial Cancer Institute Brno Czech Republic; and

See more in PubMed

Verheijen RB, Beijnen JH, Schellens JHM, et al. Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing. Clin Pharmacokinet. 2017;56:987–997.

Verheijen RB, Yu H, Schellens JHM, et al. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther. 2017;102:765–776.

Novartis; EMA. Votrient-Summary of Product Characteristics. Dublin, Ireland: Novartis; 2018.

Lankheet N, Desar I, Mulder S, et al. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol. 2017;83:2195–2204.

Groenland SL, van Eerden RAG, Westerdijk K, et al. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study. Ann Oncol. 2022;33:1071–1082.

Groenland SL, Mathijssen RHJ, Beijnen JH, et al. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. Eur J Clin Pharmacol. 2019;75:1309–1318.

Westerdijk K, Desar IME, Steeghs N, et al. Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br J Clin Pharmacol. 2020;86:258–273.

Noda S, Yoshida T, Hira D, et al. Exploratory investigation of target pazopanib concentration range for patients with renal cell carcinoma. Clin Genitourin Cancer. 2019;17:E306–E313.

Ozbey AC, Combarel D, Poinsignon V, et al. Population pharmacokinetic analysis of pazopanib in patients and determination of target AUC. Pharmaceuticals. 2021;14.

Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet. 2012;27:85–105.

Sogawa R, Nakashima C, Nakamura T, et al. Association of genetic polymorphisms with afatinib-induced diarrhoea. In Vivo. 2020;34:1415–1419.

Deng Y, Sychterz C, Suttle AB, et al. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013;43:443–453.

Ergun Y, Ozdemir NY, Toptas S, et al. Drug-drug interactions in patients using tyrosine kinase inhibitors: a multicenter retrospective study. J Buon. 2019;24:1719–1726.

Azam C, Claraz P, Chevreau C, et al. Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors. Eur J Clin Pharmacol. 2020;76:579–587.

Mir O, Touati N, Lia M, et al. Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043/62072 trials. Clin Cancer Res. 2019;25:1479–1485.

Mourey L, Le Louedec F, Ravaud A, et al. VOTRAGE study: phase I dose-escalation study of pazopanib in unfit older patients. J Geriatr Oncol. 2021;12:759–764.

Goh B, Reddy N, Dandamudi U, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88:652–659.

UpToDate. Pazopanib: Drug Information. Wolters Kluwer; 1–13; https://www.uptodate.com/contents/pazopanib-drug-information?search=pazopanib&source=panel_search_result&selectedTitle=1%7E64&usage_type=panel&kp_tab=drug_general&display_rank=1 (2023, Accessed October 13, 2023).

Iwase M, Fujita K, Nishimura Y, et al. Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38. Cancer Chemother Pharmacol. 2019;83:993–998.

Taguchi T, Masuo Y, Sakai Y, et al. Short-lasting inhibition of hepatic uptake transporter OATP1B1 by tyrosine kinase inhibitor pazopanib. Drug Metab Pharmacokinet. 2019;34:372–379.

Takasaki S, Adachi H, Kawasaki Y, et al. Importance of therapeutic drug monitoring to detect drug interaction between pazopanib and warfarin: a case report. J Pharm Pharmaceut Sci. 2020;23:200–205.

Zhong YY, McLean L, Buckle A, et al. Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab. Can J Urol. 2020;27:10339–10341.

Maillard M, Arellano C, Vachoux C, et al. Biological role of pazopanib and sunitinib aldehyde derivatives in drug-induced liver injury. Metabolites. 2022;12.

Ouchi R, Kashiwagura S, Watanabe T, et al. Pazopanib-induced liver injury in patients with metastatic renal cell carcinoma: a report of two cases. Cureus. 2022;14:e32474.

Miyamoto S, Kakutani S, Sato Y, et al. Drug review: pazopanib. Jpn J Clin Oncol. 2018;48:503–513.

Zelmat Y, Conte C, Noize P, et al. Incidence of heart failure following exposure to a protein kinase inhibitor, a French population-based study. Br J Clin Pharmacol. 2023;89:1338–1348.

Bins S, Huitema ADR, Laven P, et al. Impact of CYP3A4*22 on pazopanib pharmacokinetics in cancer patients. Clin Pharmacokinet. 2019;58:651–658.

van Eerden RAG, Ijzerman NS, van Meekeren M, et al. CYP3A4*22 genotype-guided dosing of kinase inhibitors in cancer patients. Clin Pharmacokinet. 2023.

Henriksen JN, Bøttger P, Hermansen CK, et al. Pazopanib-induced liver toxicity in patients with metastatic renal cell carcinoma: effect of UGT1A1 polymorphism on pazopanib dose reduction, safety, and patient outcomes. Clin Genitourin Cancer. 2020;18:62–68.e62.

Motzer RJ, Johnson T, Choueiri TK, et al. Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. Ann Oncol. 2013;24:2927–2928.

Qosa H, Avaritt BR, Hartman NR, et al. In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia. Cancer Chemother Pharmacol. 2018;82:795–802.

Xu CF, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer. 2010;102:1371–1377.

Bianconi M, Faloppi L, Loretelli C, et al. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. Oncotarget. 2016;7:37599–37607.

Grande E, Capdevila J, Castellano D, et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol. 2015;26:1987–1993.

Groenland SL, van Eerden RAG, Koolen SLW, et al. Therapeutic drug monitoring of pazopanib: using cost-neutral PK-guided interventions to optimize exposure. J Clin Oncol. 2020;38.

Minot MS, Rouquette PB, Jouinot A, et al. Pazopanib exposure in advanced soft tissue and bone sarcoma: a pharmacokinetic/pharmacodynamic analysis. Ann Oncol. 2021;32:S1125.

Sternberg CN, Donskov F, Haas NB, et al. Pazopanib exposure response assessment as adjuvant therapy for patients with localized or locally advanced renal cell carcinoma (RCC) following nephrectomy. J Clin Oncol. 2017;35:4564.

Sternberg CN, Donskov F, Haas NB, et al. Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma. Clin Cancer Res. 2018;24:3005–3013.

Suttle B, Ball HA, Molimard M, et al. Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC). J Clin Oncol. 2010;28.

Suttle AB, Ball HA, Molimard M, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111:1909–1916.

Verheijen RB, Swart LE, Beijnen JH, et al. Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. Cancer Chemother Pharmacol. 2017;80:1171–1178.

George DJ, Halabi S, Healy P, et al. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. Prostate. 2019;79:1752–1761.

Eriksson M, Reichardt P, Joensuu H, et al. Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST). ESMO Open. 2021;6.

Zhang Y, Fang H, Wang X, et al. The efficacy and safety of pazopanib plus chemotherapy in treating recurrent or persistent ovarian cancer: a systematic review and meta-analysis. Am J Clin Oncol. 2023;46:254–256.

Harris PA, Boloor A, Cheung M, et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem. 2008;51:4632–4640.

Fukudo M, Tamaki G, Azumi M, et al. Pharmacokinetically guided dosing has the potential to improve real-world outcomes of pazopanib. Br J Clin Pharmacol. 2021;87:2132–2139.

Minot-This MS, Boudou-Rouquette P, Jouinot A, et al. Relation between plasma trough concentration of pazopanib and progression-free survival in metastatic soft tissue sarcoma patients. Pharmaceutics. 2022;14:1–12.

Verheijen RB, Bins S, Mathijssen RHJ, et al. Individualized pazopanib dosing: a prospective feasibility study in cancer patients. Clin Cancer Res. 2016;22:5738–5746.

Tanaka H, Hiraga H, Takekuma Y, et al. Possibility for dose optimization of pazopanib from its plasma concentration in Japanese patients with cancer. Biol Pharm Bull. 2020;43:762–766.

Molenaar-Kuijsten L, Van Meekeren M, Verheijen R, et al. Intra-tumoral pharmacokinetics of pazopanib in combination with radiotherapy in patients with non-metastatic soft-tissue sarcoma. Cancers. 2021;13:1–12.

Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15:4220–4227.

Mir O, Cropet C, Toulmonde M, et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol. 2016;17:632–641.

de Wit D, van Erp NP, den HartighJ, et al. Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study. Ther Drug Monit. 2015;37:331–338.

Janssen JM, Dorlo TPC, Beijnen JH, et al. Evaluation of extrapolation methods to predict trough concentrations to guide therapeutic drug monitoring of oral anticancer drugs. Ther Drug Monit. 2020;42:532–539.

Groenland SL, van Eerden RAG, Verheijen RB, et al. Cost-neutral optimization of pazopanib exposure by splitting intake moments: a prospective pharmacokinetic study in cancer patients. Clin Pharmacokinet. 2020;59:941–948.

Heath EI, Chiorean EG, Sweeney CJ, et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88:818–823.

Lubberman FJE, Gelderblom H, Hamberg P, et al. The effect of using pazopanib with food vs. fasted on pharmacokinetics, patient safety, and preference (DIET study). Clin Pharmacol Ther. 2019;106:1076–1082.

Krens SD, Lubberman FJE, van Egmond M, et al. The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. Int J Cancer. 2021;148:2799–2806.

Takasaki S, Kawasaki Y, Kikuchi M, et al. Clinical importance of blood drug concentration of oral molecular targeted drugs for renal cell carcinoma. J Pharm Pharmaceut Sci. 2021;24:127–136.

Shiraiwa K, Suzuki Y, Tanaka K, et al. Development of a high-throughput quantification method for pazopanib using ultra-performance liquid chromatography-tandem mass spectrometry and its clinical application in patients with soft tissue tumors. Ther Drug Monit. 2021;43:416–421.

van Erp NP, de Wit D, Guchelaar HJ, et al. A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;937:33–43.

Paludetto MN, Puisset F, Le Louedec F, et al. Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS/MS. J Pharm Biomed Anal. 2018;154:373–383.

Verheijen RB, Bins S, Thijssen B, et al. Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS. Bioanalysis. 2016;8:123–134.

Matsumoto A, Shiraiwa K, Suzuki Y, et al. Sensitive quantification of free pazopanib using ultra-high performance liquid chromatography coupled to tandem mass spectrometry and assessment of clinical application. J Pharm Biomed Anal. 2021;206:1–6.

de Wit D, den Hartigh J, Gelderblom H, et al. Dried blood spot analysis for therapeutic drug monitoring of pazopanib. J Clin Pharmacol. 2015;55:1344–1350.

Espy RD, Manicke NE, Ouyang Z, et al. Rapid analysis of whole blood by paper spray mass spectrometry for point-of-care therapeutic drug monitoring. Analyst. 2012;137:2344–2349.

Toh YL, Pang YY, Shwe M, et al. HPLC-MS/MS coupled with equilibrium dialysis method for quantification of free drug concentration of pazopanib in plasma. Heliyon. 2020;6:1–6.

Dziadosz M, Lessig R, Bartels H. HPLC-DAD protein kinase inhibitor analysis in human serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;893:77–81.

Tan AR, Dowlati A, Jones SF, et al. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist. 2010;15:1253–1261.

Tan AR, Dowlati A, Stein MN, et al. Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. Br J Cancer. 2014;110:2647–2654.

Takahashi K, Saishin Y, King AG, et al. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol. 2009;127:494–499.

Infante JR, Novello S, Ma WW, et al. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. Invest New Drugs. 2013;31:927–936.

Inada-Inoue M, Ando Y, Kawada K, et al. Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors. Cancer Chemother Pharmacol. 2014;73:673–683.

Yau T, Chen PJ, Chan P, et al. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res. 2011;17:6914–6923.

Noda S, Hira D, Kageyama S, et al. Pharmacokinetic analysis of a hemodialyzed patient treated with pazopanib. Clin Genitourin Cancer. 2016;14:E453–E456.

Burris HA, Dowlati A, Moss RA, et al. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Mol Cancer Ther. 2012;11:1820–1828.

Stein J, Milhem M, Vaena D. Clinical outcomes and toxicities of pazopanib administered orally in crushed form: case reports and review of the literature. J Oncol Pharm Pract. 2020;26:232–235.

Kendra KL, Plummer R, Salgia R, et al. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Mol Cancer Ther. 2015;14:461–469.

Bennouna J, Deslandres M, Senellart H, et al. A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. Invest New Drugs. 2015;33:138–147.

Di Gion P, Kanefendt F, Lindauer A, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet. 2011;50:551–603.

Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–1068.

Sheng X, Jin J, He Z, et al. Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies. BMC Cancer. 2020;20:219.

Motzer RJ, Haas NB, Donskov F, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol. 2017;35:3916–3923.

Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722–731.

Goebell PJ, Doehn C, Grüllich C, et al. The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape. Future Oncol. 2017;13:1463–1471.

Nieto M, Borregaard J, Ersbøll J, et al. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Clin Cancer Res. 2011;17:6608–6614.

van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–1886.

Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol. 2011;29:2439.

Bartoš F, Aust F, Haaf JM. Informed Bayesian survival analysis. BMC Med Res Methodol. 2022;22:238.

Mueller-Schoell A, Groenland SL, Scherf-Clavel O, et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eurj Clin Pharmacol. 2021;77:441–464.